Biocon Biologics scores 53 in its debut on the S&P Global Corporate Sustainability Assessment for 2024

Biocon Biologics Limited, which participated independently in S&P Global’s Corporate Sustainability Assessment (CSA) for the first time, reported an S&P Global ESG Score core of 53.

The S&P Global ESG Score measures a company’s performance on and management of material ESG risks, opportunities, and impacts informed by a combination of company disclosures, media and stakeholder analysis, modeling approaches, and in-depth company engagement via the S&P Global CSA. The assessment serves as a crucial reference for stakeholders in making informed business and investment decisions.

As a purpose-driven organization, robust Environmental, Social and Governance (ESG) practices are at the foundation of what we do and guides our business practices.

We are actively working to minimize the environmental impact of our business by lowering carbon emissions, optimizing water usage, and reducing waste generation. The core of our business is to provide patients with access to lifesaving medicines and we are committed to expanding our reach in low-income and low- and middle-income countries (LICs / LMICs).